Pharmacogenetics and inflammatory bowel disease: progress and prospects.
Ho
Gwo-Tzer
GT
Department of Gastroenterology, Western General Hospital, Edinburgh EH,4 2XU. gho@ed.ac.uk
Lees
Charlie
C
Satsangi
Jack
J
D000305:Adrenal Cortex Hormones / Q000235:genetics / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005544:Forecasting; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000235:genetics*; D000069285:Infliximab; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D010597:Pharmacogenetics / Q000592:standards / Q000639:trends*; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate